Bausch Health Companies Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Bausch Health Companies Inc. (BHC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $18.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-07-30
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $6.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $12.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $36.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$32.00M, a 228.00% decline year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$36.00M, a 340.00% decline from fiscal 2024.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $15.00M, a 74.58% decline from fiscal 2023.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $59.00M, a 110.71% increase from fiscal 2022.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $28.00M, a 154.55% increase from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $18.00M 10-Q · filed 2026-07-30 | $54.00M derived: sum of 3 quarters · filed 2026-07-30 | $22.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $12.00M 10-Q · filed 2026-04-30 | $48.00M derived: sum of 2 quarters · filed 2026-04-30 | $16.00M derived: sum of 3 quarters · filed 2026-04-30 | -$13.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.00M derived: sum of 2 quarters · filed 2026-02-19 | -$25.00M derived: sum of 3 quarters · filed 2026-07-30 | -$36.00M 10-K · filed 2026-02-19 | |
| 2025-09-30 | -$32.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$61.00M derived: sum of 2 quarters · filed 2026-07-30 | -$72.00M 10-Q · filed 2025-10-30 | -$76.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$29.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$40.00M 10-Q · filed 2026-07-30 | -$44.00M derived: sum of 3 quarters · filed 2026-07-30 | -$19.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$11.00M 10-Q · filed 2026-04-30 | -$15.00M derived: sum of 2 quarters · filed 2026-04-30 | $10.00M derived: sum of 3 quarters · filed 2026-04-30 | $6.00M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $21.00M derived: sum of 2 quarters · filed 2026-02-19 | $17.00M derived: sum of 3 quarters · filed 2026-02-19 | $15.00M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $21.00M derived: sum of 2 quarters · filed 2025-10-30 | $19.00M 10-Q · filed 2025-10-30 | $38.00M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-06-30 | -$4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$6.00M 10-Q · filed 2025-07-31 | $13.00M derived: sum of 3 quarters · filed 2025-07-31 | $38.00M derived: sum of 4 quarters · filed 2025-07-31 | |
| 2024-03-31 | -$2.00M 10-Q · filed 2025-05-01 | $17.00M derived: sum of 2 quarters · filed 2025-05-01 | $42.00M derived: sum of 3 quarters · filed 2025-05-01 | $26.00M derived: sum of 4 quarters · filed 2025-05-01 | |
| 2023-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $44.00M derived: sum of 2 quarters · filed 2025-02-20 | $28.00M derived: sum of 3 quarters · filed 2025-02-20 | $59.00M 10-K · filed 2025-02-20 | |
| 2023-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $9.00M derived: sum of 2 quarters · filed 2024-10-31 | $40.00M 10-Q · filed 2024-10-31 | $66.00M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | -$16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $15.00M 10-Q · filed 2024-08-01 | $41.00M derived: sum of 3 quarters · filed 2024-08-01 | $45.00M derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | $31.00M 10-Q · filed 2024-05-02 | $57.00M derived: sum of 2 quarters · filed 2024-05-02 | $61.00M derived: sum of 3 quarters · filed 2024-05-02 | $56.00M derived: sum of 4 quarters · filed 2024-05-02 | |
| 2022-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $30.00M derived: sum of 2 quarters · filed 2024-02-22 | $25.00M derived: sum of 3 quarters · filed 2024-02-22 | $28.00M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$1.00M derived: sum of 2 quarters · filed 2023-11-02 | $2.00M 10-Q · filed 2023-11-02 | $5.00M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.00M 10-Q · filed 2023-08-03 | $1.00M derived: sum of 3 quarters · filed 2023-08-03 | $9.00M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $3.00M 10-Q · filed 2023-05-04 | $6.00M derived: sum of 2 quarters · filed 2023-05-04 | $14.00M derived: sum of 3 quarters · filed 2023-05-04 | $23.00M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $11.00M derived: sum of 2 quarters · filed 2023-02-23 | $20.00M derived: sum of 3 quarters · filed 2023-02-23 | $11.00M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $17.00M derived: sum of 2 quarters · filed 2022-11-03 | $8.00M 10-Q · filed 2022-11-03 | $30.00M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $22.00M derived: sum of 3 quarters · filed 2022-08-09 | $24.00M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$9.00M 10-Q · filed 2022-05-10 | $13.00M derived: sum of 2 quarters · filed 2022-05-11 | $15.00M derived: sum of 3 quarters · filed 2022-05-11 | $26.00M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | $22.00M derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $24.00M derived: sum of 2 quarters · filed 2022-05-11 | $35.00M derived: sum of 3 quarters · filed 2022-05-11 | $48.00M 8-K · filed 2022-05-11 | |
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $13.00M derived: sum of 2 quarters · filed 2021-11-02 | $26.00M 10-Q · filed 2021-11-02 | $36.00M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $24.00M 10-Q · filed 2021-08-03 | $34.00M derived: sum of 3 quarters · filed 2021-08-03 | $37.00M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-03-31 | $13.00M 10-Q · filed 2021-05-04 | $23.00M derived: sum of 2 quarters · filed 2021-05-04 | $26.00M derived: sum of 3 quarters · filed 2021-05-04 | $46.00M derived: sum of 4 quarters · filed 2021-05-04 | |
| 2019-12-31 | $10.00M derived: 8-K 12 month − 10-Q 9 month · filed 2021-05-04 | $13.00M derived: sum of 2 quarters · filed 2021-05-04 | $33.00M derived: sum of 3 quarters · filed 2021-05-04 | $12.00M 8-K · filed 2021-05-04 | |
| 2019-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $23.00M derived: sum of 2 quarters · filed 2020-11-03 | $2.00M 10-Q · filed 2020-11-03 | $16.00M derived: sum of 4 quarters · filed 2020-11-03 | |
| 2019-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.00M 10-Q · filed 2020-08-06 | $13.00M derived: sum of 3 quarters · filed 2020-08-06 | -$6.00M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | -$21.00M 10-Q · filed 2020-05-07 | -$7.00M derived: sum of 2 quarters · filed 2020-05-07 | -$26.00M derived: sum of 3 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | -$5.00M derived: sum of 2 quarters · filed 2020-02-19 | -$9.00M 10-K · filed 2020-02-19 | ||
| 2018-09-30 | -$19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$23.00M 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | -$4.00M 10-Q · filed 2019-08-06 | ||||
| 2016-12-31 | -$13.00M 10-K · filed 2017-03-01 | ||||
| 2015-12-31 | -$23.00M 10-K · filed 2017-03-01 | $23.00M 10-K · filed 2016-04-29 | |||
| 2014-12-31 | $14.10M 10-K · filed 2016-04-29 | ||||
| 2013-12-31 | $29.20M 10-K · filed 2015-02-25 | $29.26M 10-K · filed 2014-02-28 | |||
| 2012-12-31 | $5.27M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |